Dr. Wei Tao is an Instructor at Harvard Medical School (HMS) and Brigham and Women’s Hospital (BWH). He received his PhD in Biology from Tsinghua University. He held a postdoctoral fellowship in Prof. Omid C. Farokhzad's group at HMS/BWH from 2016 to 2018. Subsequently, he was promoted to be an Instructor in March 2018. His research focuses on the design and synthesis of functional nanomaterials including two-dimensional (2D) materials and polymeric biomaterials, exploring their nano-bio interactions and extensive biomedical applications including RNA therapeutics, cancer theranostics, wound healing, cardiovascular disease and diabetes treatment. He has published over 60 peer-reviewed papers (including 15 cover papers, 10 Top 1% ESI Highly Cited Papers, and 3 Top 0.1% ESI Hot Papers) in Nature Biomedical Engineering, Nature Communications, Chemical Society Reviews, Advanced Materials, Angewandte Chemie, Advanced Science, ACS Nano, Nano Letters, etc. He is a Member of the Frontiers Editorial Board, a Founding Editor of the Topic-“Application of Nanobiotechnology in Pharmacology” for Frontiers in Pharmacology, and is an active reviewer for numerous prestigious journals (e.g., Advanced Materials, ACS Nano, Nano Letters, Advanced Functional Materials, Materials Horizons, Advanced Drug Delivery Reviews, Small, Biomaterials, etc.). He is also a member of the Academy at Harvard Medical School. Dr. Tao currently serves as the Principal Investigator (PI) on multiple awards/grants including the U.S. METAvivor Early Career Investigator Award, Harvard Anaesthesia Department Basic Scientist Grant, and American Heart Association (AHA) Collaborative Sciences Award.